Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation.

Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, Fujisawa S, Sakura T, Okumura H, Iriyama N, Emi N, Fujimaki K, Honda S, Miyazaki Y, Naoe T.

Blood Adv. 2019 Feb 12;3(3):312-319. doi: 10.1182/bloodadvances.2018025981.

2.

Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.

Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y; and the Japanese Adult Leukemia Study Group.

Leukemia. 2019 Feb;33(2):358-370. doi: 10.1038/s41375-018-0233-7. Epub 2018 Aug 9.

PMID:
30093681
3.

Primary uterine lymphoma: The Yokohama Cooperative Study Group for Hematology (YACHT) study.

Ishii Y, Fujisawa S, Ando T, Suzuki T, Ishiyama Y, Kishimoto K, Hattori Y, Nakajima Y, Miyazaki T, Takasaki H, Matsumoto K, Koharazawa H, Taguchi J, Fujimaki K, Sakai R, Nakajima H.

Asia Pac J Clin Oncol. 2018 Jul 8. doi: 10.1111/ajco.13049. [Epub ahead of print]

PMID:
29984481
4.

Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study.

Tachibana T, Andou T, Tanaka M, Ito S, Miyazaki T, Ishii Y, Ogusa E, Koharazawa H, Takahashi H, Motohashi K, Aoki J, Nakajima Y, Matsumoto K, Hagihara M, Hashimoto C, Taguchi J, Fujimaki K, Fujita H, Fujisawa S, Kanamori H, Nakajima H; Yokohama Cooperative Study Group for Hematology (YACHT).

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):415-421. doi: 10.1016/j.clml.2018.03.009. Epub 2018 Mar 31.

PMID:
29673622
5.

Crack the state of silence: Tune the depth of cellular quiescence for cancer therapy.

Fujimaki K, Yao G.

Mol Cell Oncol. 2017 Dec 18;5(1):e1403531. doi: 10.1080/23723556.2017.1403531. eCollection 2018.

6.

A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features.

Kawamoto K, Miyoshi H, Suzuki T, Kozai Y, Kato K, Miyahara M, Yujiri T, Choi I, Fujimaki K, Muta T, Kume M, Moriguchi S, Tamura S, Kato T, Tagawa H, Makiyama J, Kanisawa Y, Sasaki Y, Kurita D, Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K.

Haematologica. 2018 Jun;103(6):1018-1028. doi: 10.3324/haematol.2017.174177. Epub 2017 Dec 14.

7.
8.

Predictors of negative symptoms in the chronic phase of schizophrenia: A cross-sectional study.

Fujimaki K, Toki S, Yamashita H, Oyamada T, Yamawaki S.

Psychiatry Res. 2018 Apr;262:600-608. doi: 10.1016/j.psychres.2017.09.051. Epub 2017 Sep 24.

PMID:
28965809
9.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group.

Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

PMID:
28929332
10.

Exit from quiescence displays a memory of cell growth and division.

Wang X, Fujimaki K, Mitchell GC, Kwon JS, Della Croce K, Langsdorf C, Zhang HH, Yao G.

Nat Commun. 2017 Aug 22;8(1):321. doi: 10.1038/s41467-017-00367-0.

11.

Body mass index is a prognostic factor in adult patients with acute myeloid leukemia.

Ando T, Yamazaki E, Ogusa E, Ishii Y, Yamamoto W, Motohashi K, Tachibana T, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Fujita H, Kanamori H, Fujisawa S, Nakajima H; Yokohama Cooperative Study Group for Hematology (YACHT).

Int J Hematol. 2017 May;105(5):623-630. doi: 10.1007/s12185-017-2183-7. Epub 2017 Jan 21.

PMID:
28110409
12.

Corrigendum: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 Nov 29;48(12):1591. doi: 10.1038/ng1216-1587a. No abstract available.

PMID:
27898077
13.

Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.

Matsuoka T, Miwa Y, Tajika M, Sawada M, Fujimaki K, Soga T, Tomita H, Uemura S, Nishino I, Fukuda T, Sugie H, Kosuga M, Okuyama T, Umeda Y.

Mol Genet Metab Rep. 2016 Nov 18;9:98-105. eCollection 2016 Dec.

14.

The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.

Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J.

Leuk Lymphoma. 2016 Dec;57(12):2763-2770. Epub 2016 Jun 20.

PMID:
27320054
15.

Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.

Yamazaki E, Kanamori H, Itabashi M, Ogusa E, Numata A, Yamamoto W, Ito S, Tachibana T, Hagihara M, Matsumoto K, Koharazawa H, Taguchi J, Tomita N, Fujimaki K, Fujita H, Fujisawa S, Ogawa K, Ishigatsubo Y.

Leuk Lymphoma. 2017 Jan;58(1):104-109. Epub 2016 Jun 7.

PMID:
27267543
16.

Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 May;48(5):569-74. doi: 10.1038/ng.3535. Epub 2016 Mar 28. Erratum in: Nat Genet. 2016 Nov 29;48(12 ):1591.

PMID:
27019113
17.

Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.

Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, Gemba K, Fujimaki K, Kirito K, Goto T, Fujisaki T, Takeda K, Nakajima A, Ueda T.

Int J Clin Oncol. 2016 Oct;21(5):996-1003. Epub 2016 Mar 26.

PMID:
27017611
18.

Cortical activation changes and sub-threshold affective symptoms are associated with social functioning in a non-clinical population: A multi-channel near-infrared spectroscopy study.

Fujimaki K, Takemoto H, Morinobu S.

Psychiatry Res Neuroimaging. 2016 Feb 28;248:73-82. doi: 10.1016/j.pscychresns.2016.01.005. Epub 2016 Jan 4.

PMID:
26774423
19.

Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.

Fujimaki K, Miyashita K, Kawasaki R, Tomita N.

Eur J Haematol. 2016 Sep;97(3):228-31. doi: 10.1111/ejh.12709. Epub 2016 Jan 3.

PMID:
26613362
20.

Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.

Miyashita K, Tomita N, Taguri M, Suzuki T, Ishiyama Y, Ishii Y, Nakajima Y, Numata A, Hattori Y, Yamamoto W, Miyazaki T, Tachibana T, Takasaki H, Matsumoto K, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.

Leuk Res. 2015 Aug 29. pii: S0145-2126(15)30368-4. doi: 10.1016/j.leukres.2015.08.016. [Epub ahead of print]

PMID:
26350140
21.

Cutting Edge: AhR Is a Molecular Target of Calcitriol in Human T Cells.

Takami M, Fujimaki K, Nishimura MI, Iwashima M.

J Immunol. 2015 Sep 15;195(6):2520-3. doi: 10.4049/jimmunol.1500344. Epub 2015 Aug 14.

22.

Evaluation of soluble interleukin-2 receptor and serum lactate dehydrogenase in malignant lymphoma.

Tomita N, Taguri M, Hashimoto C, Takasaki H, Fujimaki K, Motomura S, Koharazawa H, Takemura S, Fujita H, Yamazaki E, Kawasaki R, Taguchi J, Sakai R, Fujisawa S, Hattori Y, Kanamori H, Yamamoto W, Harano H, Ogawa K, Ishigatsubo Y.

Ann Hematol. 2015 Nov;94(11):1935-7. doi: 10.1007/s00277-015-2448-2. Epub 2015 Jul 25. No abstract available.

PMID:
26208667
23.

Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia.

Tachibana T, Tanaka M, Hagihara M, Kawasaki R, Yamazaki E, Koharazawa H, Taguchi J, Tomita N, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.

Int J Hematol. 2015 Oct;102(4):451-9. doi: 10.1007/s12185-015-1836-7. Epub 2015 Jul 15.

PMID:
26173594
24.

Expression mechanism of tryptophan hydroxylase 1 in mouse islets during pregnancy.

Iida H, Ogihara T, Min MK, Hara A, Kim YG, Fujimaki K, Tamaki M, Fujitani Y, Kim H, Watada H.

J Mol Endocrinol. 2015 Aug;55(1):41-53. doi: 10.1530/JME-14-0299. Epub 2015 Jul 1.

PMID:
26136513
25.

SET7/9 Enzyme Regulates Cytokine-induced Expression of Inducible Nitric-oxide Synthase through Methylation of Lysine 4 at Histone 3 in the Islet β Cell.

Fujimaki K, Ogihara T, Morris DL, Oda H, Iida H, Fujitani Y, Mirmira RG, Evans-Molina C, Watada H.

J Biol Chem. 2015 Jul 3;290(27):16607-18. doi: 10.1074/jbc.M115.661777. Epub 2015 May 20.

26.

[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy].

Koharazawa H, Watanabe R, Hattori Y, Numata A, Kawasaki R, Kuwabara H, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Taguchi J, Tomita N, Fujita H, Sakai R, Harano H, Ishigatsubo Y, Fujisawa S.

Rinsho Ketsueki. 2015 Apr;56(4):392-9. doi: 10.11406/rinketsu.56.392. Japanese.

PMID:
25971269
27.

R-CHOP therapy alone for limited-stage follicular lymphoma.

Tomita N, Suzuki T, Ishiyama Y, Miyashita K, Takahashi H, Numata A, Ito S, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.

Leuk Res. 2015 Jun;39(6):582-5. doi: 10.1016/j.leukres.2015.03.008. Epub 2015 Apr 6.

PMID:
25866096
28.

Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.

Ishii Y, Tomita N, Suzuki T, Ishiyama Y, Kishimoto K, Yamamoto E, Koyama S, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Takemura S, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.

Leuk Lymphoma. 2015;56(9):2750-2. doi: 10.3109/10428194.2015.1010161. Epub 2015 Mar 6. No abstract available.

PMID:
25644745
29.

Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.

Nakajima Y, Tomita N, Itabashi M, Miyashita K, Watanabe R, Miyazaki T, Tachibana T, Takasaki H, Kawasaki R, Tanaka M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Harano H, Motomura S, Ishigatsubo Y.

Leuk Res. 2015 Feb;39(2):198-203. doi: 10.1016/j.leukres.2014.11.030. Epub 2014 Dec 8.

PMID:
25541027
30.

Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.

Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suenobu S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG).

Blood Cancer J. 2014 Oct 17;4:e252. doi: 10.1038/bcj.2014.72.

31.

Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial.

Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K, Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T.

J Clin Oncol. 2014 Nov 20;32(33):3729-35. doi: 10.1200/JCO.2013.53.3570. Epub 2014 Sep 22. Erratum in: J Clin Oncol. 2015 Jan 10;33(2):228.

PMID:
25245439
32.

Comparative transcriptomic analysis of two closely related ground beetle species with marked genital divergence using pyrosequencing.

Fujimaki K, Fujisawa T, Yazawa S, Nishimura O, Sota T.

Zoolog Sci. 2014 Sep;31(9):587-92. doi: 10.2108/zs140081.

PMID:
25186930
33.

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.

Nakajima Y, Tomita N, Watanabe R, Ishiyama Y, Yamamoto E, Ishibashi D, Itabashi M, Koyama S, Takahashi H, Numata A, Takasaki H, Kawasaki R, Kuwabara H, Tanaka M, Hashimoto C, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.

Med Oncol. 2014 Sep;31(9):185. doi: 10.1007/s12032-014-0185-3. Epub 2014 Aug 21.

PMID:
25142947
34.

Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type.

Yamazaki E, Tomita N, Koyama S, Ogusa E, Ishii Y, Takahashi H, Miyashita K, Matsuura S, Tachibana T, Takasaki H, Takemura S, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y.

Med Oncol. 2014 Sep;31(9):149. doi: 10.1007/s12032-014-0149-7. Epub 2014 Aug 10.

PMID:
25108598
35.

Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.

Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.

Leuk Lymphoma. 2015 Mar;56(3):725-9. doi: 10.3109/10428194.2014.931953. Epub 2014 Aug 6.

PMID:
24913502
36.

Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan.

Numata A, Tanaka M, Matsumoto K, Takasaki H, Tachibana T, Fujimaki K, Sakai R, Fujisawa S, Tomita N, Fujita H, Maruta A, Ishigatsubo Y, Kanamori H.

Clin Transplant. 2014 Apr;28(4):403-9. doi: 10.1111/ctr.12324. Epub 2014 Mar 21.

PMID:
24655161
37.

Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.

Tomita N, Kodama F, Tsuyama N, Sakata S, Takeuchi K, Ishibashi D, Koyama S, Ishii Y, Yamamoto W, Takasaki H, Hagihara M, Kuwabara H, Tanaka M, Hashimoto C, Yamazaki E, Koharazawa H, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y.

Hematol Oncol. 2015 Mar;33(1):9-14. doi: 10.1002/hon.2136. Epub 2014 Feb 11.

PMID:
24519501
38.

European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.

Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, Hashimoto C, Itabashi M, Ishibashi D, Nakajima Y, Tachibana T, Kawasaki R, Kuwabara H, Koharazawa H, Yamazaki E, Tomita N, Sakai R, Fujita H, Kanamori H, Ishigatsubo Y.

Cancer Sci. 2014 Jan;105(1):105-9. doi: 10.1111/cas.12321. Epub 2014 Jan 23.

39.

Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.

Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.

Eur J Haematol. 2014 Mar;92(3):204-10. doi: 10.1111/ejh.12221. Epub 2013 Nov 28.

PMID:
24283206
40.

Transcriptome dynamics in early embryos of the ascidian, Ciona intestinalis.

Matsuoka T, Ikeda T, Fujimaki K, Satou Y.

Dev Biol. 2013 Dec 15;384(2):375-85. doi: 10.1016/j.ydbio.2013.10.003. Epub 2013 Oct 9.

41.

MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy.

Yamamoto E, Tomita N, Sakata S, Tsuyama N, Takeuchi K, Nakajima Y, Miyashita K, Tachibana T, Takasaki H, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Harano H, Motomura S, Ishigatsubo Y.

Cancer Sci. 2013 Dec;104(12):1670-4. doi: 10.1111/cas.12288. Epub 2013 Nov 27.

42.

Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients.

Tachibana T, Tanaka M, Numata A, Matsumoto K, Tomita N, Fujimaki K, Taguchi J, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.

Leuk Lymphoma. 2014 Jun;55(6):1350-6. doi: 10.3109/10428194.2013.842981. Epub 2013 Nov 1.

PMID:
24024470
43.

Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.

Tomita N, Takasaki H, Fujisawa S, Miyashita K, Ogusa E, Kishimoto K, Matsuura S, Sakai R, Koharazawa H, Yamamoto W, Fujimaki K, Fujita H, Ishii Y, Taguchi J, Kuwabara H, Motomura S, Ishigatsubo Y.

J Clin Exp Hematop. 2013;53(2):121-5.

44.

Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, Miyashita K, Matsuura S, Fujisawa S, Hattori Y, Takasaki H, Fujita A, Ohshima R, Kuwabara H, Hashimoto C, Fujimaki K, Sakai R, Ishigatsubo Y.

Leuk Res. 2013 Oct;37(10):1208-12. doi: 10.1016/j.leukres.2013.07.015. Epub 2013 Aug 5.

PMID:
23927994
45.

[Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].

Miyashita K, Fujimaki K, Ishigatsubo Y.

Gan To Kagaku Ryoho. 2013 Mar;40(3):405-7. Japanese.

PMID:
23507609
46.

R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.

Tomita N, Takasaki H, Miyashita K, Fujisawa S, Ogusa E, Matsuura S, Kishimoto K, Numata A, Fujita A, Ohshima R, Kuwabara H, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Fujimaki K, Taguchi J, Sakai R, Ishigatsubo Y.

Br J Haematol. 2013 May;161(3):383-8. doi: 10.1111/bjh.12281. Epub 2013 Feb 25.

PMID:
23432318
47.

Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.

Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group.

Blood. 2013 Apr 18;121(16):3095-102. doi: 10.1182/blood-2012-11-466862. Epub 2013 Feb 14.

48.

Negative correlation between affective symptoms and prefrontal activation during a verbal fluency task: a near-infrared spectroscopy study.

Sawa M, Yamashita H, Fujimaki K, Okada G, Takahashi T, Yamawaki S.

Neuropsychobiology. 2013;67(2):103-10. doi: 10.1159/000345161. Epub 2013 Feb 9.

PMID:
23407267
49.

Multicenter validation of scoring system of pre-transplant serum ferritin and disease risk in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplant.

Tachibana T, Tanaka M, Yamazaki E, Numata A, Takasaki H, Kuwabara H, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.

Leuk Lymphoma. 2013 Jun;54(6):1318-20. doi: 10.3109/10428194.2012.730613. Epub 2012 Nov 1. No abstract available.

PMID:
22989327
50.

[Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].

Numata A, Fujimaki K, Aoshima T, Onizuka M, Hagihara M, Miyazaki K, Fujita H, Sakai R, Machida S, Tanaka E, Nakajima Y, Hattori Y, Tanaka M, Yamazaki E, Shirasugi Y, Inoue Y, Watanabe S, Fujisawa S.

Rinsho Ketsueki. 2012 Jul;53(7):698-704. Japanese.

PMID:
22975772

Supplemental Content

Loading ...
Support Center